Caroline Seymour

IBI3003 received fast track designation from the regulatory agency in the setting of relapsed/refractory multiple myeloma.

Gotistobart received orphan drug designation from the FDA for patients with squamous NSCLC.

HS-20093 demonstrated durable responses and disease control in relapsed/refractory osteosarcoma and STS in phase 2 ARTEMIS-002 trial data presented at ESMO 2025.

Legubicin significantly improved PFS vs doxorubicin in advanced soft tissue sarcoma, with reduced cardiotoxicity and consistent benefit across subgroups.

Ianalumab plus ibrutinib showed promising efficacy and uMRD rates with manageable safety in a phase 1b study of patients with CLL.

Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post–limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

The EMA is reviewing a Type II variation application to expand teclistamab’s label for use with SC daratumumab in relapsed/refractory myeloma.

Frontline zanubrutinib regimens achieved objective response rates of 100% with deep remissions in elderly and younger, high-risk patients with MCL.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.

Frontline dasatinib was linked to frequent T315I mutations at relapse in Ph+ ALL, while ponatinib showed fewer resistance mutations and favorable outcomes.

Muzastotug has been granted fast track designation by the FDA for use in combination with pembrolizumab as treatment for patients with MSS mCRC.

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Final data from the BRUIN trial show pirtobrutinib achieved an 81.6% ORR and durable outcomes with a favorable safety profile in previously treated CLL/SLL.

ctDNA at end of treatment strongly predicted outcomes across lymphoma subtypes, outperforming imaging and supporting its role in personalized disease monitoring.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

Adding loncastuximab tesirine to glofitamab led to activity irrespective of disease status in relapsed/refractory diffuse large B-cell lymphoma.

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

The FDA has granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis.

AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

Seven provinces have agreed to reimburse cemiplimab for the treatment of patients with advanced non–small cell lung cancer and basal cell carcinoma.

TACE plus pembrolizumab and lenvatinib did not improve OS vs TACE alone in patients with unresectable HCC.

Zenocutuzumab has received BTD from the FDA for patients with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.

First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.